Omnitrope’s Impact on Liver Enzymes in American Males: A Decade-Long Retrospective Study

Introduction

Omnitrope, a recombinant human growth hormone, has been widely used for various medical conditions, including growth hormone deficiency and Turner syndrome. Despite its therapeutic benefits, concerns have been raised regarding its potential impact on liver function. This article presents a comprehensive retrospective analysis of liver enzyme levels over a decade in American males treated with Omnitrope, providing valuable insights into the drug's safety profile.

Study Design and Methodology

This retrospective study analyzed data from American males aged 18 to 65 who received Omnitrope treatment between 2010 and 2020. Liver function was assessed by monitoring levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at baseline and at regular intervals throughout the treatment period. The study population was stratified based on age, duration of treatment, and dosage to identify potential risk factors associated with liver enzyme elevations.

Results: Liver Enzyme Levels Over Time

The analysis revealed that the majority of American males treated with Omnitrope maintained stable liver enzyme levels throughout the study period. At baseline, the mean ALT, AST, and GGT levels were within the normal range for all age groups. Over the ten-year follow-up, only a small percentage of patients (less than 5%) experienced transient elevations in liver enzymes, which resolved without intervention or dosage adjustment.

Impact of Age and Treatment Duration

Further stratification of the data by age and treatment duration showed no significant correlation between these factors and liver enzyme levels. American males across all age groups and those receiving Omnitrope for varying durations demonstrated similar patterns of stable liver function. This finding suggests that the impact of Omnitrope on liver enzymes is not influenced by age or the length of treatment.

Dosage and Liver Enzyme Elevations

The study also investigated the potential relationship between Omnitrope dosage and liver enzyme elevations. Patients were categorized into low, medium, and high dosage groups based on their prescribed regimen. The analysis revealed no significant differences in liver enzyme levels among the dosage groups, indicating that Omnitrope dosage does not appear to be a risk factor for liver enzyme elevations in American males.

Clinical Implications and Safety Profile

The results of this decade-long study provide reassuring evidence regarding the safety of Omnitrope in relation to liver function in American males. The low incidence of transient liver enzyme elevations and the absence of significant risk factors suggest that Omnitrope can be safely used for the treatment of growth hormone deficiency and other approved indications. However, healthcare providers should continue to monitor liver function in patients receiving Omnitrope, as with any medication, to ensure early detection and management of potential adverse effects.

Limitations and Future Research

While this study provides valuable insights into the impact of Omnitrope on liver function, it is not without limitations. The retrospective nature of the analysis and the reliance on existing medical records may introduce potential biases. Future prospective studies with larger sample sizes and more comprehensive liver function assessments could further validate these findings and provide additional information on the long-term safety of Omnitrope in American males.

Conclusion

In conclusion, this retrospective analysis of liver enzyme levels over ten years in American males treated with Omnitrope demonstrates a favorable safety profile with regard to liver function. The majority of patients maintained stable liver enzyme levels, and only a small percentage experienced transient elevations that resolved without intervention. These findings support the continued use of Omnitrope for approved indications while emphasizing the importance of regular monitoring of liver function in patients receiving this medication.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.